Targeting of PI3K-a and CDK4/6 kinases in mantle cell lymphomas with dual kinase inhibitor ON 123300-lactate

被引：0
|
作者：
Akula, Balireddy [1 ]
Divakar, Saikrishna A. [2 ]
Bharathi, Vijaya E. [2 ]
Mallireddigari, Muralidhar R. [1 ]
Subbaiah, D. R. C. Venkata [2 ]
Pallela, Venkat R. [1 ]
Billa, Vinay K. [2 ]
Cosenza, Stephen C. [2 ]
Reddy, E. Premkumar [2 ]
Reddy, M. V. Ramana [2 ]
机构：
[1] Onconova Therapeut Inc, Dept Med Chem, Newtown, PA 18940 USA
[2] Icahn Sch Med Mt Sinai, Dept Med Chem, New York, NY 10029 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
493-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
    S K A Divakar
    M V Ramana Reddy
    S C Cosenza
    S J Baker
    D Perumal
    A C Antonelli
    J Brody
    B Akula
    S Parekh
    E Premkumar Reddy
    Leukemia, 2016, 30 : 86 - 93
  • [2] Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
    Divakar, S. K. A.
    Reddy, M. V. Ramana
    Cosenza, S. C.
    Baker, S. J.
    Perumal, D.
    Antonelli, A. C.
    Brody, J.
    Akula, B.
    Parekh, S.
    Reddy, E. Premkumar
    LEUKEMIA, 2016, 30 (01) : 86 - 93
  • [3] Targeting CDK4/6 inhibitor resistance in relapsed osteosarcoma via PI3 Kinase inhibition.
    Barghi, Farinaz
    Pandya, Pankita H.
    Saadatzadeh, M. Reza
    Bijangi-Vishehsaraei, Khadijeh
    Bailey, Barbara J.
    Dobrota, Erika A.
    Young, Courtney
    Trowbridge, Melissa A.
    Coy, Kathy
    Sinn, Anthony L.
    Shannon, Harlan E.
    Renbarger, Jamie L.
    Pollok, Karen E.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
    Karimi, Leena
    Alves, Carla L.
    Terp, Mikkel G.
    Tuttolomondo, Martina
    Portman, Neil
    Ehmsen, Sidse
    Johansen, Lene E.
    Bak, Martin
    Lim, Elgene
    Ditzel, Henrik J.
    CANCER COMMUNICATIONS, 2023, 43 (06) : 720 - 725
  • [5] Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 is effective in vitro and in vivo in Multiple Myeloma
    Perumal, Deepak
    Thirukonda, Venu
    Jiang, Zewei
    Leshchenko, Violetta V.
    Kuo, Pei-Yu
    Shahnaz, Samira
    Rubel, Jennifer
    Zhang, Weijia
    Cho, Hearn Jay
    Reddy, M. V. Ramana
    Reddy, E. Premkumar
    Parekh, Samir
    CANCER RESEARCH, 2014, 74 (19)
  • [6] Molecular Targeting and Inactivation of Glutaminase and CDK4/6 in Mantle Cell Lymphoma
    Gibbs, Bettine E.
    Masamha, Chioniso P.
    FASEB JOURNAL, 2018, 32 (01):
  • [7] Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER plus breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor.
    Karimi, Leena
    Alves, Carla L.
    Terp, Mikkel G.
    Tuttolomondo, Martina
    Ditzel, Henrik J.
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Effect of gender on the rodent pharmacokinetics of ON 123300, a dual inhibitor of ARK5 and CDK4/6, for the treatment of cancer
    Ren, Chen
    Mudunuru, Jennypher
    Taft, David
    Maniar, Manoj
    CANCER RESEARCH, 2018, 78 (13)
  • [9] Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats
    Mudunuru, Jennypher
    Ren, Chen
    Taft, David R.
    Maniar, Manoj
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (04) : 531 - 538
  • [10] Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats
    Jennypher Mudunuru
    Chen Ren
    David R. Taft
    Manoj Maniar
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 531 - 538
12345